Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2015

01-02-2015 | R&D Insight Report

Olaparib: First Global Approval

Author: Emma D. Deeks

Published in: Drugs | Issue 2/2015

Login to get access

Abstract

Olaparib (Lynparza™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by AstraZeneca for the treatment of solid tumours. The primary indication that olaparib is being developed for is BRCA mutation-positive ovarian cancer. A capsule formulation of the drug has received approval for use in this setting in the EU and USA, and a tablet formulation is in global phase III trials (including in the USA, EU, Australia, Brazil, Canada, China, Israel, Japan, Russia and South Korea). In addition, phase III trials in breast, gastric and pancreatic cancer are underway/planned, and phase I/II investigation is being conducted in other malignancies, including prostate cancer, non-small cell lung cancer, Ewing’s sarcoma and advanced cancer. This article summarizes the milestones in the development of olaparib leading to this first approval for ovarian cancer.
Literature
1.
Girolimetti G, Perrone AM, Santini D, et al. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int. 2014;2014:787143.PubMedCentralPubMedCrossRef
2.
3.
4.
5.
6.
7.
8.
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.PubMedCrossRef
9.
Bundred N, Gardovskis J, Jaskiewicz J, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs. 2013;31(4):949–58.PubMedCrossRef
10.
Dedes KJ, Wilkerson P, Wetterskog D, et al. PARP-inhibitor olaparib in the treatment of ovarian clear cell cancer: predictors of sensitivity and resistance [abstract no. 1113]. Lab Invest. 2012;92:265A.CrossRef
11.
12.
Im SA, Min A, Hur HS, et al. Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells [abstract no. 1775]. In: 101st Annual Meeting of the AACR; 2010.
13.
Hodgson D, Mason H, Oplustilova L, et al. Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic [abstract no. 2398]. In: AACR annual meeting; 2014.
14.
Tinhofer I, Mariya BF, Niehr F, et al. The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells [abstract no. e16018]. J Clin Oncol. 2012;30(15 Suppl 1).
15.
Knights C, Chresta C, Riches L, et al. Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer [abstract no. A114]. In: 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2009.
16.
Pierce A, McGowan PM, Cotter M, et al. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther. 2013;14(6):537–45.PubMedCentralPubMedCrossRef
17.
Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008;14(12):3916–25.PubMedCrossRef
18.
Konstantinopoulos PA, Wilson AJ, Saskowski J, et al. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol. 2014;133(3):599–606.PubMedCrossRef
19.
Choi YE, Battelli C, Watson J, et al. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014;5(9):2678–87.PubMedCentralPubMed
20.
Dey N, Wu H, Sun Y, et al. Preclinical efficacy of the combination of olaparib plus carboplatin with vandetanib in triple-negative breast cancer [abstract no. e13579]. J Clin Oncol. 2012;30(15 Supp 1).
21.
Hashimoto J, Kitamura Y, Takashima Y, et al. Synergistic interaction between olaparib, a parp inhibitor, and cytotoxic agent in triple negative breast cancer [abstract no. O3–049]. Ann Oncol. 2013;24(Suppl 9):ix59.CrossRef
22.
Minami D, Takigawa N, Takeda H, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013;11(2):140–8.PubMedCrossRef
23.
Musi E, Ambrosini G, Schwartz GK. The parp inhibitor olaparib (AZD2281) greatly enances the effect of temozolomide in soft tissue sarcoma cell lines [abstract no. 2073]. Cancer Res. 2013;73(8 Suppl 1).
24.
Yamauchi T, Uzui K, Nishi R, et al. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells. Anticancer Res. 2014;34(10):5487–94.PubMed
25.
Miura K, Sakata KI, Someya M, et al. The combination of olaparib and camptothecin for effective radiosensitization. Radiat Oncol. 2012;7 (article no. 62). doi:10.​1186/​748-717X-7-62.
26.
Senra JM, Telfer BA, Cherry KE, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10(10):1949–58.PubMedCentralPubMedCrossRef
27.
Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011;17(4):783–91.PubMedCrossRef
28.
Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105(44):17079–84.PubMedCentralPubMedCrossRef
29.
Min A, Im S-A, Yoon Y-K, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol Cancer Ther. 2013;12(6):865–77.PubMedCrossRef
30.
Daemen A, Wolf DM, Korkola JE, et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat. 2012;135(2):505–17.PubMedCentralPubMedCrossRef
31.
Ang JE, Clarkson-Jones JA, Swaisland H, et al. A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments [abstract no. 405]. In: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2010.
32.
Vergote I, Rutten A, Rolfo CD, et al. Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation [abstract no. 2599]. J Clin Oncol. 2014;32(15 Suppl 1).
33.
34.
Clarkson-Jones J, Page C, Sarda S, et al. Human biotransformation of olaparib (AZD2281) an oral poly(ADP-ribose) polymerase (PARP) inhibitor [abstract no. 417]. In: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2010.
35.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.PubMedCrossRef
36.
Matulonis UA, Harter P, Gourley C, et al. Analysis of intermediate clinical endpoints from a phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [abstract no. 132]. Gynecol Oncol. 2014;133(Suppl 1):54–5.CrossRef
37.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.PubMedCrossRef
38.
Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2011;30(4):372–9.PubMedCrossRef
39.
Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–51.PubMedCrossRef
40.
Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61.PubMedCrossRef
41.
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–9.PubMedCrossRef
42.
Molife LR, Mateo J, McGoldrick T, et al. Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations [abstract no. 3048]. J Clin Oncol. 2012;30(15 Suppl 1).
43.
Mateo J, Friedlander M, Sessa C, et al. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation [abstract no. 801]. In: European Cancer Congress; 2013.
44.
Liu JF, Tolaney SM, Birrer M, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49(14):2972–8.PubMedCentralPubMedCrossRef
45.
Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14.PubMedCrossRef
46.
Lee J-M, Hays JL, Annunziata CM, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106(6):dju089.PubMedCrossRef
47.
Matulonis U, Wulf GM, Birrer MJ, et al. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC) [abstract no. 2510]. In: 50th Annual Meeting of ASCO; 2014.
48.
Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2014. doi:10.​1016/​S1470-2045(14)71135-0.
49.
Rivkin SE, Iriarte D, Sloan H, et al. Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients [abstract no. 5527]. J Clin Oncol. 2014;32(15 Suppl 1).
50.
51.
Choy E, Butrynski JE, Harmon DC, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813.PubMedCentralPubMedCrossRef
52.
Yamamoto N, Nokihara H, Yamada Y, et al. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012;103(3):504–9.PubMedCrossRef
53.
Del Conte G, Sessa C, von Moos R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014;111(4):651–9.PubMedCrossRef
54.
Balmana J, Tung NM, Isakoff SJ, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014;25(8):1656–63.PubMedCrossRef
55.
Van Der Noll R, Ang JE, Jager A, et al. Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors [abstract no.2579]. J Clin Oncol. 2013;31(15 Suppl 1).
56.
Van der Noll R, De Greve J, Jager A, et al. Safety results from a phase I study with a new tablet formulation of olaparib (O) in combination with carboplatin (C) and paclitaxel (Pa) [abstract no. 846]. In: European Cancer Congress; 2013.
57.
Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106(3):468–74.PubMedCentralPubMedCrossRef
58.
Khan OA, Gore M, Lorigan P, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011;104(5):750–5.PubMedCentralPubMedCrossRef
59.
Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012;18(8):2344–51.PubMedCrossRef
60.
Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2012;30(4):1493–500.PubMedCrossRef
61.
Waxweiler TV, Bowles D, Reddy K, et al. Safety and feasibility update of olaparib, an orally bioavailable PARP inhibitor, with concurrent cetuximab and radiation therapy in heavy smokers with stage III-IVB squamous cell carcinoma of the head/neck: a phase 1 trial [abstract no. 2884]. Int J Radiation Oncol Biol Phys. 2014;90(1 Suppl):S559.CrossRef
62.
Chalmers AJ, Jackson A, Swaisland H, et al. Results of stage 1 of the oparatic trial: a phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma [abstract no. 2025]. J Clin Oncol. 2014; 32 (15 Suppl).
63.
Garcia Campelo R, Felip E, Massuti T, et al. Phase IB study to evaluate the efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive advanced non-small-cell lung cancer (NSCLC) patients (pts). (NCT = 1513174/GECP-GOAL) [abstract no. 3420]. Eur J Cancer. 2013;49:S802–3.
64.
Chiou VL, Kohn EC, Annunziata CM, et al. Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062) [abstract no. CT337]. In: 105th Annual Meeting of the AACR; 2014.
65.
Dent RA, Lindeman GJ, Clemons M, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013;15(5):R88.PubMedCentralPubMedCrossRef
66.
Bang YJ, Im SA, Lee KW, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study [abstract no. 4013]. In: 49th Annual Meeting of ASCO; 2013.
67.
Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44.PubMedCrossRef
68.
69.
70.
Moore KN, Di Silvestro P, Lowe ES, et al. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm) [abstract no. TPS5616]. J Clin Oncol. 2014;32(15 Suppl 1).
71.
AstraZeneca. AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients [media release]. 31 May 2014. www.​astrazeneca.​com.
72.
AstraZeneca Global. Lynparza™ approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer [media release]. 18 Dec 2014. http://​astrazeneca.​com.
73.
Metadata
Title
Olaparib: First Global Approval
Author
Emma D. Deeks
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0345-6

Other articles of this Issue 2/2015

Drugs 2/2015 Go to the issue

Adis Drug Evaluation

Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency

Review Article

Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

Adis Drug Evaluation

Simeprevir: A Review of Its Use in Patients with Chronic Hepatitis C Virus Infection

Erratum

Erratum to: Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer

Adis Drug Evaluation

Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis

Adis Drug Evaluation

Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia